Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.9841
-0.0459 (-4.46%)
At close: Jun 27, 2025, 4:00 PM
1.000
+0.016 (1.62%)
After-hours: Jun 27, 2025, 7:58 PM EDT
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$47,600
Profits / Employee
-$605,316
Market Cap
287.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OCGN News
- 5 days ago - Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases - GlobeNewsWire
- 9 days ago - Ocugen: Three Potential Gene-Therapy Filings By 2028 - Seeking Alpha
- 12 days ago - Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - GlobeNewsWire
- 17 days ago - Ocugen To Present at BIO International Convention 2025 - GlobeNewsWire
- 23 days ago - Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - GlobeNewsWire
- 4 weeks ago - Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - GlobeNewsWire
- 7 weeks ago - Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewsWire